Navamedic continues to operate in Benelux markets throughout year 2015

Navamedic ASA today announced that the Company will continue its Benelux operations until the year-end after an agreement with the Company's main supplier Aspen Pharma.

The Benelux market currently accounts for approximately 20 per cent of Navamedic's total sales.

As previously announced, the two companies agreed that Aspen during the third quarter 2015 would start serving the Benelux market directly, enabling Navamedic to focus fully on sales growth in its Nordic home market.

Navamedic and Aspen have now agreed to postpone the hand-over to 1 January 2016.

"We are happy that Aspen Pharma have chosen to continue with Navamedic as distributor in Benelux for the remaining five months of the year, allowing both parties to ensure a smooth handover process. From next year Navamedic will widen its partnership with Aspen Pharma as we take on additional products from Aspens portfolio in the Nordic markets." says Tom Rönnlund, CEO of Navamedic.

For further information, please contact CEO Tom Rönnlund, telephone +46 727 320 321 or CFO Bjørn Lindholt, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, delivering products to hospitals and pharmacies in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical products manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).